Technology as the Foundation, Rigor as the Principle
At Waton Corporation, we believe that true medical innovation must be built on safety and compliance. Every therapy, cell sample, and clinical procedure we perform adheres to the highest standards set by Japan’s Ministry of Health, Labour and Welfare and is overseen through a multi-tiered review system.
We don’t just provide medical treatments; we are building a scientific system that can be trusted globally.
Research & Development Core
Our R&D team is composed of medical doctors from Japan, bioengineers, and AI health scientists, focusing on three key areas: regenerative medicine, exosome research, and AI-driven medical applications.
Three Core R&D Directions:
Stem Cell Exosome Research
Explore intercellular communication mechanisms and develop exosome extraction technology with regeneration induction capabilities.
AI Health Data Modeling
Building a health database that integrates behavioral analysis and physiological monitoring to provide personalized treatment recommendations.
Exploration of Immune Repair Mechanisms
Focusing on chronic inflammation and cellular aging repair, we are developing a next-generation anti-aging model.
Our technology stems from the accumulation of clinical data and the dedication of our scientists.
Laboratory Standards
Item | Description |
Level | Compliant with Japan’s Ministry of Health, Labour and Welfare GMP standards (Good Manufacturing Practice). |
Environmental Control | Sterility Level Class 100, with constant temperature and humidity systems and fully automated monitoring. |
Quality Tracking | Each batch of cells is assigned a unique traceable ID, with records maintained for over 10 years. |
Personnel Standards | All personnel are certified as CPC (Cell Preparation Chief) Supervisors. |
Operating Procedures | From sample collection, culturing, and cryopreservation to infusion, the entire process follows standardized SOPs. |
The laboratory uses a closed culture system and high-purity processing techniques to ensure that each cell line grows safely under conditions free from contamination, viruses, and exogenous DNA.
This is not just quality control—it is a reflection of our medical responsibility.
Regulatory Compliance
Japan Ministry of Health, Labour and Welfare: Act on the Safety of Regenerative Medicine
All treatments are registered under Japan’s official “Regenerative Medicine Provision Plan” and have been approved by a third-party Institutional Review Board (IRB).
Primary Plan Numbers:
- Regenerative Medicine Class II: PB3160029 (Stem Cell Intravenous Infusion)
- Regenerative Medicine Class III: PB3180127 (PRP Platelet-Rich Plasma Therapy)
Regulatory Authority:
- Ministry of Health, Labour and Welfare (MHLW)
- Japan Medical Association Institutional Review Board (IRB)
- GMP Cell Culture and Clinical Operation Audit Center
Safety Report System:
All cases must submit reports on efficacy and side effects, which are reviewed and archived by a third-party committee.
Compliance is the foundation of medical trust.
AI × Medical Data Integration
We employ AI computing and cross-analysis of clinical databases, enabling regenerative medicine to move beyond single-point experience and validate efficacy through big data.
AI System Applications:
- Case Data Modeling and Health Prediction
- Personalized Treatment Plan Recommendations
- Monitoring Stem Cell Quality and Efficacy
- Clinical Efficacy Visualization and Statistics
The system integrates clinical data from both Japan and Taiwan, continuously refining efficacy algorithms to ensure that each patient’s treatment plan is grounded in precision medicine.
AI makes regenerative medicine more precise, more personalized, and more trustworthy.
International Collaboration & Knowledge Co-Creation
We collaborate with multiple international research institutions to develop new regenerative medicine technologies:
- University of Tokyo Hospital, Japan
- Kyoto University Center for iPS Cell Research and Application (CiRA)
- Collaboration with medical universities in Japan
- Agency for Science, Technology and Research (ASTAR), Singapore
Through cross-border clinical data exchange and AI analysis sharing, we are establishing Asia’s first "International Cell Database."
This is not only scientific collaboration but also a bridge of medical trust.
Intellectual Property & Research Achievements
- 2022 | Exosome Purification Technology Patent (JP-2022-31789)
- 2023｜AI Stem Cell Quality Monitoring System Patent (JP-2023-59071)
- 2024｜Regenerative Medicine Clinical Monitoring Platform Patent (TW-2024-23150)
Research Papers Citing Journals:
- Journal of Stem Cell Research
- Asian Clinical Regenerative Medicine Review
- Cell Therapy and Molecular Science
Every patent we hold is an extension and validation of our clinical achievements.
Compliance Declaration
Science must be validated; medicine must be trusted.
Waton Corporation pledges:
All treatments are based on clinical science, regulatory compliance, and ethical principles.
All treatments are performed by licensed Japanese medical doctors.
All data is traceable, verifiable, and auditable.
